BioCryst Pharma (BCRX) Reports Q4 Loss Per Share of 6c

BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.06), $0.17 better than the analyst estimate of ($0.23). Revenue for the quarter came in at $9 million versus the consensus estimate of $4.13 million.

For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance